AC Immune SA (ACIU)

Market Cap	263.59M
Revenue (ttm)	n/a
Net Income (ttm)	-79.67M
Shares Out	83.41M
EPS (ttm)	-1.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	88,906
Open	3.27
Previous Close	3.29
Day's Range	2.96 - 3.29
52-Week Range	2.06 - 8.14
Beta	0.71
Analysts	Buy
Price Target	10.88 (+244.3%)
Earnings Date	Nov 7, 2022

About ACIU

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Ph...

• Industry: Biotechnology
• IPO Date: Sep 23, 2016
• CEO: Andrea Pfeifer
• Employees: 137
• Stock Exchange: NASDAQ
• Ticker Symbol: ACIU

Full Company Profile

Financial Performance

Financial numbers in CHF Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for ACIU stock is "Buy." The 12-month stock price forecast is 10.88, which is an increase of 244.30% from the latest price.

Price Target

$10.88

(244.30% upside)

Analyst Consensus: Buy

Stock Forecasts